Anti-CD91 antibody [A2Mr alpha-2] (STJ16100538)

SKU:
STJ16100538-01

$848.48
Shipping:
Free Shipping
Current Stock:
Host: Mouse
Applications: WB/IP/FC/IHC-F/ELISA
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Mouse monoclonal antibody anti-CD91 is suitable for use in Western Blot, Immunoprecipitation, Flow Cytometry, Immunohistochemistry and ELISA research applications.
Clonality: Monoclonal
Clone ID: A2Mr alpha-2
Conjugation: Unconjugated
Isotype: IgG1
Formulation: PBS with 0.09% sodium azide
Concentration: 1.0mg/mL
Storage Instruction: Store at 2-8°C upon receipt.
Immunogen: Purified alpha2 macroglobulin receptor
Background Mouse anti Human CD91 antibody, clone A2Mr alpha-2 recognizes human CD91, also known as Prolow-density lipoprotein receptor-related protein 1, Alpha-2-macroglobulin receptor or apolipoprotein E receptor. CD91 is a 4525 amino acid protein post translationally cleaved into 3 subunits, a 85 kDa type I transmembrane carboxyl chain (LRP85) non-covalently bound to a 515 kDa extracellular N-terminal subunit (LRP515) containing multiple EGF-like and LDL-receptor Class A and Class B domains. Additionally, there is an intracellular domain (LRPICD) which can be cleaved from the transmambrane domain by gamma secretase (May et al. 2004). Clone A2Mr alpha-2 detects an epitope within the LRP515 chain.CD91 is a multifunctional protein involved in processes inluding the phagocytosis and endocytosis of apoptotic cells (Nilsson et al. 2012) , clearance of activated serum alpha-2-macroglobulin (Kristensen et al. 1990) , modulation of the inflammatory response (Staudt et al. 2013) and acts as a receptor for Pseudomonas aeruginosa exotoxin A (Kounnas et al. 1992).Mouse anti Human CD91, clone A2Mr alpha-2 has been used extensively for the detection of CD91 by flow cytometry and immunohistochemistry

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance